ARECOR THERAPEUTICS PLC
Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.
AREC | IL
Overview
Corporate Details
- ISIN(s):
- GB00BMWLM973
- LEI:
- 98450093D12I3A8DDD58
- Country:
- United Kingdom
- Address:
- Chesterford Research Park, CB10 1XL Saffron Walden
- Website:
- https://arecor.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Arecor Therapeutics plc is a globally focused biopharmaceutical company that develops enhanced therapeutic medicines by applying its proprietary Arestat™ technology platform. The company's primary business involves reformulating existing pharmaceutical products to improve their stability, efficacy, and delivery methods, thereby transforming patient care. Arecor operates a dual business model: developing its own proprietary portfolio of medicines, with a key focus on treatments for diabetes and obesity (such as an oral GLP-1 agonist), and partnering with leading pharmaceutical and medtech companies to enhance their therapeutic products. The Arestat™ platform is supported by a robust intellectual property portfolio and aims to address significant unmet patient needs in high-value markets.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-17 12:50 |
Major Shareholding Notification
Holding(s) in Company
|
English | 50.7 KB | ||
| 2025-11-11 11:05 |
Major Shareholding Notification
Holding(s) in Company
|
English | 50.4 KB | ||
| 2025-11-04 08:30 |
Regulatory News Service
Enhanced IP Coverage: AT278 & Oral Peptide Program
|
English | 14.9 KB | ||
| 2025-09-29 08:00 |
Board/Management Information
Directorate Changes
|
English | 23.1 KB | ||
| 2025-09-24 10:30 |
Report Publication Announcement
Notice of Interim Results
|
English | 13.0 KB | ||
| 2025-09-04 08:00 |
Regulatory News Service
Positive FDA Feedback on Phase 2 Study Design
|
English | 18.2 KB | ||
| 2025-08-28 13:00 |
Major Shareholding Notification
Holding(s) in Company
|
English | 23.4 KB | ||
| 2025-08-08 08:00 |
Audit Report / Information
Change of Auditor
|
English | 13.2 KB | ||
| 2025-07-14 08:00 |
Regulatory News Service
Arecor Establishes New Scientific Advisory Board
|
English | 18.0 KB | ||
| 2025-06-02 14:32 |
Post-Annual General Meeting Information
Result of AGM
|
English | 25.5 KB | ||
| 2025-06-02 08:00 |
Board/Management Information
Non-Executive Director Board Change
|
English | 15.2 KB | ||
| 2025-05-06 17:42 |
Report Publication Announcement
Posting of 2024 Annual Report and Notice of AGM
|
English | 13.6 KB | ||
| 2025-04-22 08:00 |
Annual Report
Final results for 2024
|
English | 334.0 KB | ||
| 2025-03-26 08:00 |
M&A Activity
Collaboration with global pharmaceutical partner
|
English | 16.3 KB | ||
| 2025-03-12 08:00 |
Regulatory News Service
Arecor partnership with biopharmaceutical company
|
English | 17.5 KB |
Automate Your Workflow. Get a real-time feed of all ARECOR THERAPEUTICS PLC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ARECOR THERAPEUTICS PLC
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ARECOR THERAPEUTICS PLC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
